Companies › Isofol Medical
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Arfolitixorin 5,10-methenyltetrahydrofolate synthetase inhibitor; active metabolite of leucovorin for 5- | MTHFR | Phase 1 | Metastatic Colorectal Cancer (mCRC) | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06922383 | Arfolitixorin | Phase 1 | Metastatic Colorectal Cancer (mCRC) | Oncology | Nov 2028 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.